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48 C.M. Crosby et al. / Virology Reports 5 (2015) 47–55Vaccines are the most economical medical intervention to control infectious agents, yet tr
vaccine strategies have struggled to control some of the more difﬁcult pathogens (reviewed
1999). In the late 1980s, “genetic vaccines” were invented that circumvented the need to prod
teins in the laboratory and purify them. They instead use the vaccinated host's own cells to pro
vaccines in situ. By this approach, single genes encoded in simple plasmids can be delivered dir
a person's cells in vivo using a gene gun or needle injection (Acsadi et al., 1991; Johnston et
McCabe et al., 1988; Sanford et al., 1987; Wolff et al., 1992; Wolff et al., 1990; Wolff et al., 19
et al., 1990). Once delivered, the DNA is transcribed and translated into the pathogen protein
generate vaccine responses as if the host has been infected. In essence, the host cell becomes
to produce the protein vaccine. Importantly, this in situ intracellular production of pathogen
from a plasmid not only produces antibodies, but also allows protein display on major histoco
ity complex (MHC) I and II molecules on the host cells. This MHC display of genetic vaccine
drives CD4 and CD8 T cell responses that are important to kill intracellular pathogens. Base
gene-based vaccines have been extensively applied against human immunodeﬁciency viru
and against its models simian immunodeﬁciency virus (SIV), and SIV-HIV chimeras (SHIVs) (
in (Barry, 2012)).
If one relies on a gene to express vaccine antigens, the genes that are usedmust translate proteins
ly. Early work using with HIV-1 envelope plasmids demonstrated that these were surprising
expressed considering that these are human viruses (Boyer, 1997; Fuller et al., 1997; Lu et al., 199
due in part to the poor codon bias of HIV genes relative to the tRNA pools that are present in ma
cells (Haas et al., 1996).
To avoid this problem, one can “codon-optimize” genes by replacing their codons that are s
low abundance tRNAs with codons with better tRNA pools. When applied for HIV envelope, c
timization increased expression 100-fold (Haas et al., 1996). Increasing antigen expression
increases immune responses after genetic immunization (Andre et al., 1998), so this approac
come common practice for gene-based vaccines. These positive effects may not be due
increased protein translation. More recent studies suggest that codon-optimization can alte
folding (Komar et al., 1999). Other work indicates that codon-optimized sequences may be
ciently N-glycosylated (Honarmand Ebrahimi et al., 2014; Ujvari et al., 2001). For proteins
envelope, this may have positive effects if lower glycosylation better reveals protein epito
versely, if too little of the protein is glycosylated, this may impede secretion or display on
surface.
SIV and SHIV are important challenge viruses to test candidate HIV vaccines in non-hu
mates. Therefore, the vaccines that are tested in these models must be homologous or
the ﬁnal challenge virus. Most SIV or SHIV vaccines utilize the SIV gag protein and eith
HIV envelope depending on the challenge virus (reviewed in (Barouch and Korber, 2010)).
tion with SIV gag alone can generate immunodominant T cell responses in some cases aga
one epitope that can be easily escaped by viral mutation (Barouch et al., 2003; Barou
2002). Considering this, generating multivalent T cell responses against more than one
may limit the ability of viruses to mutationally escape HIV vaccines. While gag has many
to be targeted by CD4 and CD8 T cell responses, it is less than half the size of pol. Therefore,
ing both gag and pol may supply a richer repertoire of T cell epitopes for multivale
responses.
The gag-pol protein may be an attractive antigen. However, pol is out of frame with g
only expressed after a translational frame shift. This translates into the expression of appro
one molecule of pol for every 10 of gag. Given these issues, in this work, we codon-optimize
gag-pol sequence from SIVmac239. To increase pol expression, we synthetically changed it
frame to bypass the need for frame shifting for its expression. Finally, we inserted four “se
ing” picornavirus sequences into gag p24, protease, reverse transcriptase, and into integras
ment the proteins for potentially better immune presentation. Here we evaluate the
expression of these novel immunogens and test their ability to drive antibody and T cell r
in vivo in mice.
2. Materials and methods
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Fig. 1. Schematic of wild-type and codon-optimized SIV gag-pol expression cassettes.
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A549 cells were purchased from (ATCC, Manassas, VA) andweremaintained in Dulbecco's modi
medium supplementedwith 10% fetal bovine serum (FBS; HyClone, Rockford, IL) and penicillin/stre
at 100 U/mL (Invitrogen).
2.2. Codon-optimized gag-pol fusion protein genes
The gag-pol sequence from SIVmac239 (accession number AY588946 (O'Connor et al., 2004)) w
design the SIV gag-pol fusion protein. The 534 amino acids constituting the p55 gag protein were
frame in silico with the ﬁrst amino acid of the 1138 amino acid pol protein that is produced by fr
during gag-pol expression (Jacks et al., 1988). This 1672 amino acid sequence was also modiﬁed t
the second amino acid of gag from glycine to an alanine to prevent myristylation and membrane
to improve antigen degradation and presentation (Wong and Siliciano, 2005). In addition, a His
added to the c-terminus of the virtual protein for detection and puriﬁcation. To improve the ability o
teasome to cleave the proteins, four picornavirus “self-cleaving” 2A peptides (Szymczak et al., 20
inserted into the middle of gag p24, protease (PRO), reverse transcriptase (RT), and integrase (IN
and Supplemental Fig. 1). The inserted sequences included glycine–glycine–serine (GGS) ﬂexibilit
using native G or S amino acids where possible (Table 1). Insertion sites were selected tominimize d
of native reading frame. The self-cleaving sequences were inserted into SIV gag-pol fusion with two
Table 1
Self-cleaving insertions in gag-pol fusion cleaver protein.
SIV protein Cleavage site Inserted sequencea
p24 P2A GGSATNFSLLKQAGDVEENPG*PGGS
PRO E2a GGSQCTNYALLKLAGDVESNPG*PGGS
RT T2A GGSEGRGSLLTCGDVEENPG*PGGS
INT F2A GGSVKQTLNFDLLKLAGDVESNPG*PGGS
a The full picornavirus cleavage sequence from (Szymczak et al., 2004) is underlined and the intended cleavage site between G and P is
marked with an asterisk.
restriction sites ﬂanking each as follows: P2A was ﬂanked by AfeI sites, E2A was ﬂanked by BbvCI sites, T2A
wasﬂanked by SpeI sites, and F2Awas ﬂanked byXhoI sites. This in silico polypeptide called SIV gag-pol fusion
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50 C.M. Crosby et al. / Virology Reports 5 (2015) 47–55cleaver (Fig. 1 and Supplemental Fig. 1) was used to generate a virtual human codon-optimized
quence using the GeneBuilder program (UT Southwestern). This virtual sequence was used by
(Piscataway, NJ) to synthesize the SIV gag-pol fusion cleaver cDNA. This sequence was then seq
restriction digested and ligated with AfeI, BbvCI, SpeI, and XhoI to remove the cleavage sites and g
parallel SIV gag-pol fusion protein without self-cleaving functions.
2.3. Adenovirus vectors
The SIV gag-pol fusion cleaver and SIV gag-pol fusion cDNAs were cloned into pShuttle-CMV
Ad-Easy system (QBiogene), and this plasmidwas recombinedwith the adenovirus serotype 5 (Ad5
pAd-Easy1. This plasmidwas cutwith PacI, theDNApuriﬁed, and used to transfect 293 cells. Both vir
rescued and ampliﬁed with ﬁnal production from a Cell Factory (Corning) as in (Parrott et al., 20
virus was puriﬁed by double banding on CsCl gradients and viral particle (vp) concentration was qu
by OD260.
2.4. In vitro protein expression
293 cells were transfected with 4 μg of each of the pShuttle-CMV plasmids described above usin
Polyfect Transfection Reagent (Qiagen), and western blotting was performed. To test expression
vectors, A549 cells were infected with Ad5-CMV-SIV gag-pol fusion and gag-pol fusion cleaver at
cell. Lysates were harvested 48 h after transfection or infection and proteins separated on 10% S
gels prior to transfer to polyvinylidene diﬂuoride (PVDF) membrane. The membranes were blocke
dried milk in Tris-buffered saline with 0.1% Tween 20 (TBST). Blots were probed with a 1/1000 diluti
mac251 p17 Gag Monoclonal (KK59) antibody from the AIDS Reagent program for one hour at room
ature. Blots were washed in TBST and probed with a 1/2000 dilution of goat anti-mouse-hor
peroxidase (HRP) secondary antibody (Pierce Chemical) for one hour. Blots were washed and HR
tected with West Femto Chemiluminescent reagent (Pierce).
2.5. Immunizations
Female BALB/c mice were purchased from Harlan Sprague–Dawley (Indianapolis, IN). They we
in the Mayo Clinic Animal Facility under the Association for Assessment and Accreditation of Labor
imal Care (AALAC) guidelines with animal use protocols approved by the Mayo Clinic Animal Use
Committee. All animal experiments were carried out according to the provisions of the Animal W
PHS Animal Welfare Policy, the principles of the NIH Guide for the Care and Use of Laboratory Ani
the policies and procedures of Mayo Clinic. Mice were immunized with 1010 vp of the indicated v
PBS by the intramuscular (i.m.) route and boostedwith the same amount after 3weeks. Sampleswe
ed and immune responses were measured at the indicated times.
2.6. Enzyme-linked immunosorbent assay (ELISA)
At indicated times, blood was collected in BD microtainer tubes with serum separator (Becton
and Company) from the submandibular vein. Samples were stored at −20 °C until assayed. Im
HBX plates (Thermo, Milford, MA) were coated with 100 ng/well SIV gag p24 in PBS at room tem
at 4 °C overnight. Wells were blocked with 3% BSA, 1× PBS at room temperature for 1 h. Mouse s
diluted 1:100 in 3% BSA, 1× PBS, and applied to plates at room temperature 2 h. Wells wer
with 1xPBS and rabbit anti-mouse IgG (Pierce Chemical) was added at a 1:4000 dilution for 2
were washed and the plates were developed with 100μL 1 step Ultra TMB ELISA (Thermo Fisher
Inc, Rockford, IL). Fifty microliters of 2N H2SO4 was added to each well to quench development an
was measured using the Beckman Coulter DTX 880 Multimode Detector system.
2.7. SIV gag-speciﬁc IFN-γ ELISPOT
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51C.M. Crosby et al. / Virology Reports 5 (2015) 47–55Fresh splenocytes were isolated after euthanasia of the mice as in Weaver and Barry (20
these were stimulated with select overlapping SIVmac239 gag peptide pools (MGVRNSVLS
NSVLSGKKADELEKI, SGKKADELEKIRLRP, HAEEKVKHTEEAKQI, KVKHTEEAKQIVQRH, TEEAKQIVQ
KQIVQRHLVVETGTT, QRHLVVETGTTETMP, VVETGTTETMPKTSR, DVKQGPKEPFQSYVD, GPKEPFQSY
PFQSYVDRFYKSLRA, YVDRFYKSLRAEQTD, CGKMDHVMAKCPDRQ, DHVMAKCPDRQAGFL, AKCP
LGLGP, DRQAGFLGLGPWGKK) containing CD4 and CD8 T cell epitopes identiﬁed in BALB/c mice
2009) or with Con A (5 μg/ml) as a positive control. 1 × 106 splenocytes were seeded in 96-w
backed plates (MAIP S 45,Millipore, Bedford, MA) previously coatedwith anti-IFN-γ. The cells were
with antigens for 36 h at 37 °C,were then removed, and thewellswerewashed prior to incubationw
of alkaline-phosphatase-conjugated anti-IFN-γ for 2 h at room temperature. Spots representing i
cells secreting IFN-γ were detected using BCIP/ NBT. The plates were washed and the spots were
by Zellnet Consulting (New Jersey, NJ). Responses in terms of IFN-γ spot-forming cells (SFC) are rep
for 105 total input PBMC were determined for individual macaques after subtracting background.
represent the background of the assay as it is twice the number observed in cells cultured in the m
2.8. Data analysis
Graphs and statistical analyses were performed using Prism Graphical software.
3. Results
3.1. Codon-optimized gag-pol fusion protein genes
The SIVmac239 (Jacks et al., 1988) p55 gag open reading frame (ORF) was fused in frame in s
the ﬁrst amino acid of the pol protein. This produced a single open reading frame of 1672 amFig. 2.Western blot analysis of protein expression by SIV gag-pol fusion andSIV gag-pol fusion cleaver. (A) 293 cellswere transfectedwith
plasmids expressing the indicated constructs and lysates were separated on SDS–PAGE gels prior to western blotting with anti-SIV gag
p17 or anti-His6. (B) 293 cells were infected with Ad5 vectors expressing the indicated constructs and western blotting was performed
with anti-p17.
Since the gag and pol ORFs normally overlap by approximately 550 base pairs (bp), fusing them in frame
would normally create a direct tandem sequence repeat that would be prone to rearrangement. However,
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52 C.M. Crosby et al. / Virology Reports 5 (2015) 47–55when the sequence was codon-optimized, these previously overlapping identical sequences were
at their third codon positions rendering them no longer homologous.
This virtual sequence was modiﬁed to improve immunogenicity and detection. First, a His
added to the c-terminus of the protein. The second amino acid of gag wasmutated from glycine t
to prevent myristoylation to improve antigen presentation for CD8 T cell responses (Wong and
2005). Previous work has shown that expressing HIV gag as fragments improves proteasome de
and MHC I presentation (Sykes and Johnston, 1999). To express one protein, but potentially clea
fragments, we introduced four different picornavirus “self-cleaving” 2A peptides (Szymczak et
into gag p24, protease (PRO), reverse transcriptase (RT), and integrase (INT) (Fig. 1, Supplemen
Table 1).
This in silico polypeptide was used to generate a codon-optimized cDNA sequence. During this d
cleavage sites were each ﬂanked by two matching restriction endonuclease sites to allow remo
cleavage sites (Fig. 1). After synthesis, SIV gag-pol fusion cleaver was sequentially digested rem
sites to produce the codon-optimized sequence SIV gag-pol fusion (Fig. 1). Both sequences were in
into replication-defective adenovirus serotype 5 (Ad5) vectors for testing.
3.2. Protein expression
293 cells were transfected with expression vectors carrying each of the fusion proteins, and wes
were performed using anti-SIV gag p17 and anti-His6 (Fig. 2). Probing the n-terminus of the fusio
with anti-p17 detected bands migrating approximately at molecular weights of 15, 18, and 25 kD
the gag-pol fusion construct. This construct expresses intact SIV protease (PRO), so protein processi
sible by this enzyme (Fig. 1). In contrast in the cleaver construct, anti-p17 detected these bands, a la
of approximately 75 kDa, as well as a blob of over-exposed protein between (Fig. 2A). Since gag is 5
detection of the 75 kDa band suggests that at least part of the pol portion of the fusion protein is e
After Ad5 vectors were produced, A549 cells were infected with the vectors at 1,000 vp/cell an
were analyzed with the anti-p17 antibody (Fig. 2B). The previously unresolved blob now resolved
bands of at approximately 45 and 55 kDa for the cleaved construct (Fig. 2B). While SIV gag antib
readily available, the dearth of SIV pol antibodies prevented conﬁrmation of pol expression. Pro
anti-His6 failed to detect bands negating the ability to detect c-terminal fragments (Fig. 2A).
The protease of the fusion cleaver protein is disrupted by insertion of the E2A sequence, so the
bands may result from proteolysis of the fusion protein by cellular proteases or the inserted self-cle
quences. P2A self-cleavage would be predicted to generate a p17-tagged protein of approximatel
E2A cleavagewould generate a p17 containing protein of approximately 62 kDa if no other cleavage
T2A and F2A would generate proteins of 96 and 145 kDa with no other proteolysis. The cleaved
expressed bands of approximately 15, 18, 25, 45, 55, and 75 kDa with p17 on their n-termini s
some may have been produced by 2A cleavage, perhaps combined with cellular protease activity.
3.3. Immunization of mice expressing SIV gag-pol constructs
Western blot analysis suggest that the SIV gag-pol fusion antigen is expressed and its cleavag
driven by PRO and cellular proteases. In contrast, the fusion cleaver construct generated a differen
of cleavage perhaps driven by the 2A sequences alone or in combination with cellular proteases
these variations affected the immunogenicity of the constructs, eachwas cloned into replication-def
enovirus serotype 5 (Ad5) vectors. These were then used to immunize groups of female BALB/c m
1010 vp by the intramuscular route.
3.4. Antibody responses
Three weeks after priming immunization, sera were collected and assayed by ELISA for anti-gag
bodies. Antibody levels were virtually identical for the two constructs (Fig. 3A). The animals wer
with the same amount of vector and their sera were tested again 3 weeks later revealing similar antibody
levels in the mice.
V-speciﬁc
rated de-
he fusion
onstruct.
V gag-pol
tions that
escaped
ving mul-
ag. Given
g protein
irus self-
Fig. 3. Immune responses generated by SIV gag-pol constructs. Groups of 5 BALB/cmicewere immunized by the intramuscular routewith
1010 vp of the indicated vectors or PBS once (prime) or twice (boost). (A) Anti-SIV gag p24 ELISAswere performed. (B) Anti-SIV gag IFN-g
ELISPOTs were performed on splenocytes and responses are expressed as cytokine spot-forming cells (SFCs) per million cells. One-way
ANOVA with Bonferroni multiple comparison post-test demonstrated **p b 0.01.
53C.M. Crosby et al. / Virology Reports 5 (2015) 47–553.5. T cell responses
At the 6-week time point, the animals were sacriﬁced and their splenocytes were assayed for SI
T cell responses by ELISPOT (Fig. 3B). Splenocytes from mice vaccinated with both constructs gene
tectable IFN-γ spot-forming cells (SFCs) after stimulation with SIV gag peptide pools. However, t
protein without cleavage sequences actually generated stronger T cell responses than the cleaved c
4. Discussion
This antigen engineering study was motivated by the pragmatic need for a codon-optimized SI
expression construct for vaccine testing. Expressing both gag and pol was motivated by observa
vaccination with SIV gag alone can generate immunodominant T cell responses that can be easily
by the viral mutation (Barouch et al., 2003; Barouch et al., 2002). To maximize the likelihood of dri
tivalent T cell responses in pol, its large reading frame were pulled into the same reading frame as g
the expense of synthesizing a 5,000 base pair codon-optimized gene, we also explored if modulatin
cleavage might modify T cell and antibody responses against the antigen by inserting picornav
cleavage sequences into the protein.
This work demonstrated that the two codon-optimized sequences were expressed and that use of native
SIV polymerase or the 2A self-cleaving sequences produced differing patterns of protein fragments. These
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.03.002.
54 C.M. Crosby et al. / Virology Reports 5 (2015) 47–55studies were facilitated by the availability of antibodies against SIV gag, but were limited by a lack o
and antibodies representing SIV pol. Data from the cleaved construct suggested that at least part o
translated in the large fusion, but lack of His6 antibody staining made it unclear if the full fu
expressed. Considering that non-codon-optimized gag-pol is translated, it is likely that the fu
optimized cDNA is as well.
When these genes were used in ﬁrst generation Ad5 vectors in mice, both antigens generated
responses against at least the gag domain of the fusion protein. Both vectors generated similar an
sponses against gag p24 antigen. The SIV gag-pol fusion construct appeared to generate somewha
T cell responses against SIV gag peptide pools, although these were not signiﬁcantly different f
other. These data suggest that both constructsmay have utility in SIV protection studies and that fur
ies may be warranted to explore the utility of protein cleavage to drive immune responses.
Supplementary data to this article can be found online at http://dx.doi.org/10.1016/j.virep.2015
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